Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone

NCT00890305

Last updated date
Study Location
The Cancer Center of Huntsville, PC
Huntsville, Alabama, 35801, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Metastatic Colorectal Cancer
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Patient's age is 18 years or older, both genders.

2. Patients with metastatic disease who are eligible for first line FOLFOX chemotherapy. Adjuvant or neoadjuvant given at least 12 months prior for non-metastatic disease is permitted.

3. ECOG performance status ≤ 1

4. At least 4 weeks from prior major surgery or radiotherapy.

5. Life expectancy >3 months

6. Hematology: ANC ≥ 1.5X109/L; Platelets >100x109/L.

7. Adequate Renal function

8. Adequate Hepatic functions

9. Normal Cardiac function

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. Patients who had adjuvant or neoadjuvant therapy for non-metastatic disease given
within the last 12 months.


2. Patients who had received Oxaliplatin within 12 months prior to diagnosis of
metastatic disease.


3. Patients on concurrent anti cancer therapy other than that allowed in the study.


4. Patients on concurrent steroids, other than those allowed for routine antiemetics, or
inhaled steroids


5. Presence of clinically apparent or suspected brain metastasis.


6. Patients who have had myocardial infarction, severe congestive heart failure, or
significant arrhythmia within the past 6 months.


7. Serious active infection at the time of pre-study screening.


8. Active or history of autoimmune disorders/conditions.


9. Women who are pregnant or lactating


10. Concurrent active malignancy.


11. Ascites, pleural effusions, or osteoblastic bone metastases as the only site of
disease.


12. Other prior malignancies, except for cured or adequately treated malignancies for
which there has been no evidence of activity for more than 5 years.


13. Subjects with a condition which may interfere with the subjects' ability to understand
the requirements of the study.


14. Patients with history of life threatening allergic reactions to food or drugs


15. Patients with symptomatic peripheral neuropathy> Grade 1.


16. Known positive HIV, Hepatitis B surface antigen or Hepatitis C antibody.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Metastatic Colorectal CancerPhase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
NCT01927341
  1. Los Angeles, California
  2. New York, New York
  3. Leuven,
  4. Toronto, Ontario
  5. Toulouse Cedex 9,
  6. Milano, MI
  7. Amsterdam,
  8. Barcelona, Catalunya
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Metastatic Colorectal CancerA Phase I/II Study of IXO With Bevacizumab in Patients With Metastatic Colorectal Cancer
NCT00819754
  1. Ottawa, Ontario
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Metastatic Colorectal CancerBiweekly Versus Triweekly Raltitrexed With Oxaliplatin (With or Without Bevacizumab) in First-line Metastatic Colorectal Cancer
NCT02821559
  1. Besançon,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Metastatic Colorectal CancerToxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants
NCT00138060
  1. Grenoble,
  2. Grenoble,
  3. Pierre Benite,
  4. Pierre Benite,
  5. Saint-Priest-en-Jarez,
  6. Toulouse,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone
Official Title  ICMJE Phase II Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone Administered Intravenously to Patients With Colorectal Adenocarcinoma Previously Untreated for Metastatic Disease
Brief Summary This clinical trial will be performed in previously untreated patients with metastatic colorectal cancer. The study will evaluate the safety, tolerability and efficacy of the study drug, CT-011, in combination with FOLFOX chemotherapy (FOLFOX4 or mFOLFOX6) compared with treatment by FOLFOX alone.
Detailed Description The proposed clinical trial will be a multi-center, randomized, open label, active control study in previously untreated patients with metastatic colorectal cancer aimed to evaluate the safety, tolerability and efficacy of the monoclonal antibody, CT-011, administered at 3mg/kg in combination with FOLFOX chemotherapy (FOLFOX4 or mFOLFOX6) compared with treatment by FOLFOX alone. Approximately 168 patients are planned to be enrolled to this study.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Metastatic Colorectal Cancer
Intervention  ICMJE
  • Drug: CT-011
  • Drug: FOLFOX

    FOLFOX-4: each cycle consists of the following: oxaliplatin 85 mg/m2 on Day 1, leucovorin 200 mg/m2/day on Day 1 and Day 2 followed by 5-FU 400 mg/m2 bolus and a 22 hour infusion of 5-FU 600 mg/m2 for two consecutive days.

    mFOLFOX-6: each cycle consists of the following: oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 on Day 1, followed by 5-FU 400 mg/m2 bolus, followed by 5-FU 1200 mg/m2/day for two consecutive days (total 2,400 mg/m2 over 46-48 hours).

Study Arms  ICMJE
  • Experimental: CT-011 in combination with FOLFOX

    CT-011 (3 mg/kg) administered intravenously every 4 weeks for 4 weeks and every 12 weeks thereafter until disease progression or maximum tolerance.

    FOLFOX (FOLFOX4 or mFOLFOX6) administered 7 days after the first administration of CT-011 and repeated every 14 days for up to 24 cycles. At the end of FOLFOX therapy, patients who have not progressed will be eligible for maintenance chemotherapy with 5-FU/leucovorin at the same dose and schedule until disease progression or study drug discontinuation.

    Interventions:
    • Drug: CT-011
    • Drug: FOLFOX
  • Active Comparator: FOLFOX
    FOLFOX (FOLFOX-4 or mFOLFOX6) administered every 14 days for up to 24 cycles. At the end of FOLFOX therapy, patients who have not progressed will be eligible for maintenance chemotherapy with 5-FU/leucovorin at the same dose and schedule until disease progression or study drug discontinuation.
    Intervention: Drug: FOLFOX
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: June 18, 2013)
171
Original Estimated Enrollment  ICMJE
 (submitted: April 28, 2009)
168
Actual Study Completion Date  ICMJE March 2013
Actual Primary Completion Date May 2012   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Patient's age is 18 years or older, both genders.
  2. Patients with metastatic disease who are eligible for first line FOLFOX chemotherapy. Adjuvant or neoadjuvant given at least 12 months prior for non-metastatic disease is permitted.
  3. ECOG performance status ? 1
  4. At least 4 weeks from prior major surgery or radiotherapy.
  5. Life expectancy >3 months
  6. Hematology: ANC ? 1.5X109/L; Platelets >100x109/L.
  7. Adequate Renal function
  8. Adequate Hepatic functions
  9. Normal Cardiac function

Exclusion Criteria:

  1. Patients who had adjuvant or neoadjuvant therapy for non-metastatic disease given within the last 12 months.
  2. Patients who had received Oxaliplatin within 12 months prior to diagnosis of metastatic disease.
  3. Patients on concurrent anti cancer therapy other than that allowed in the study.
  4. Patients on concurrent steroids, other than those allowed for routine antiemetics, or inhaled steroids
  5. Presence of clinically apparent or suspected brain metastasis.
  6. Patients who have had myocardial infarction, severe congestive heart failure, or significant arrhythmia within the past 6 months.
  7. Serious active infection at the time of pre-study screening.
  8. Active or history of autoimmune disorders/conditions.
  9. Women who are pregnant or lactating
  10. Concurrent active malignancy.
  11. Ascites, pleural effusions, or osteoblastic bone metastases as the only site of disease.
  12. Other prior malignancies, except for cured or adequately treated malignancies for which there has been no evidence of activity for more than 5 years.
  13. Subjects with a condition which may interfere with the subjects' ability to understand the requirements of the study.
  14. Patients with history of life threatening allergic reactions to food or drugs
  15. Patients with symptomatic peripheral neuropathy> Grade 1.
  16. Known positive HIV, Hepatitis B surface antigen or Hepatitis C antibody.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Bulgaria,   India,   Peru,   Puerto Rico,   Romania,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00890305
Other Study ID Numbers  ICMJE CT-2008-01
2009-014593-18 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Medivation, Inc.
Study Sponsor  ICMJE Medivation, Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator:Leonard B Saltz, MDMemorial Sloan Kettering Cancer Center
PRS Account Medivation, Inc.
Verification Date June 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP